As more data are gathered on teprotumumab for use in thyroid eye disease (TED), we’ll have a better understanding of which subgroups respond better or worse to the treatment, explained Robert G. Fante, MD, FACS, president of the American Society of Ophthalmic Plastic & Reconstructive Surgery and facial plastic surgeon and cosmetic surgeon, Fante Eye & Face Centre in Denver, Colorado.
As more data is gathered on the treatment of teprotumumab for thyroid eye disease (TED), we’ll have a better understanding of which subgroups respond better or worse to the treatment, explained Robert G. Fante, MD, FACS, president of the American Society of Ophthalmic Plastic & Reconstructive Surgery and facial plastic surgeon and cosmetic surgeon, Fante Eye & Face Centre in Denver, Colorado.
Transcript
The pivotal studies for teprotumumab have had pretty small cohorts. What are the benefits we'll see when we start getting larger patient population studies?
I think there'll be a lot of benefits from that. Clearly the studies have been powerful enough to give us statistical significance to permit the FDA to act and to allow all of us to be able to use this drug and feel like we have a reasonably good chance of success.
That said, as we have larger cohorts and more information, we'll have a lot more data; it'll be useful to help us recognize which subgroups it's most helpful for or which subgroups is least helpful for, or whether that turns out to be any variation between men and women, for example, or among children and adults or whether there's particular subtypes that we cannot identify clinically, for whom we decide this is the great the best therapy we've got or perhaps there's something better.
Also, I suspect that as research goes on, we'll learn about other kinds of drugs that are similar that may still be in the pipeline that might be helpful. So, I suspect that the future for this is very bright, both for this drug and our ability to use it effectively in patients as we get more data and have more controlled trials that are available to us. And then also for the future of thyroid eye disease, that this will be the beginning of a new era in treatment where instead of dealing only with some of the most obvious problems and, sort of secondarily, dealing with symptoms with things like surgery, we’ll have a way to prevent some of the problems, substantially limiting the burden on society, and, obviously, the burden on individual patients.
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Age Alone Is No Barrier to Allo-HCT for AML, Data Indicate
April 17th 2024A new study is among the largest real-world analyses to date to assess trends over time and predictive factors for older patients with acute myeloid leukemia (AML) who received allogeneic hematopoietic cell transplantation (allo-HCT).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More